Ret On Web

Can progression of geographic atrophy( GA) in Dry AMD be prevented?? As we know, there are more than 5 million people affected with GA, with high chance of 35 to 50 % development of GA in other whom there is advanced GA in one eye.    Currently the antiVEGF what we have can lead to increase in progresion of GA than to prevent it. Recently ,  Lampalizumab (Genentech) is an antigen-binding fragment of a humanized monoclonal antibody directed against complement factor D has been currently being evaluated in two identical phase 3 trials in patients with GA: Spectri (NCT02247531) and Chroma (NCT02247479). So in future we may have treatment for prevention of progression of GA in high risk people